Analyst Price Targets — AORT
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| June 16, 2026 10:36 am | William Plovanic | Canaccord Genuity | $36.00 | $21.07 | StreetInsider | Canaccord Reiterates Buy Rating on Artivion Inc. (AORT) |
| June 1, 2026 11:29 am | John McAulay | Stifel Nicolaus | $45.00 | $22.19 | StreetInsider | Stifel Reiterates Buy Rating on Artivion (AORT) |
| March 5, 2026 12:57 pm | John McAulay | Stifel Nicolaus | $55.00 | $38.26 | StreetInsider | Artivion (AORT) Reiterated at Buy by Stifel After Physician Conversations |
| December 17, 2025 9:31 am | William Plovanic | Canaccord Genuity | $51.00 | $45.91 | StreetInsider | Canaccord Genuity Reiterates Buy Rating on Artivion Inc. (AORT) |
| November 7, 2025 11:11 am | Suraj Kalia | Oppenheimer | $50.00 | $45.73 | StreetInsider | Artivion Inc. (AORT) PT Raised to $50 at Oppenheimer |
| August 8, 2025 11:09 am | Mike Matson | Needham | $45.00 | $39.27 | StreetInsider | Artivion Inc. (AORT) PT Raised to $45 at Needham |
| October 23, 2024 3:32 am | Daniel Stauder | JMP Securities | $33.00 | $26.53 | StreetInsider | JMP Securities Starts Artivion Inc. (AORT) at Market Outperform |
| August 9, 2024 7:52 am | Suraj Kalia | Oppenheimer | $30.00 | $25.33 | StreetInsider | Artivion Inc. (AORT) PT Raised to $30 at Oppenheimer |
| July 10, 2024 9:08 am | Frank Takkinen | Lake Street | $30.00 | $25.94 | TheFly | Lake Street highlights five 'bargain bin' small cap healthcare ideas for 2H |
| July 2, 2024 8:49 am | Frank Takkinen | Loop Capital Markets | $30.00 | $26.02 | StreetInsider | Artivion Inc. (AORT) PT Raised to $30 at Lake Street Capital Markets |
Latest News for AORT
AORT's FDA approval for AMDS removes a key hospital adoption hurdle and opens access to an estimated $150 million annual U.S. market.
Artivion benefits from FDA premarket approval of AMDS, removing adoption barriers and unlocking a $150M U.S. TAM in acute aortic dissection. AMDS's clinical data shows reduced mortality and major adverse events, with the elimination of DANE tears and durable benefit, supporting rapid, adoption-driven commercial scaling. AORT demonstrates double-digit revenue growth, margin expansion, and a shift to GAAP…
ATLANTA, June 29, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and Drug Administration (FDA) has approved the premarket approval application (PMA) for the AMDS Hybrid Prosthesis ("AMDS"). The approval covers acute Debakey Type I aortic dissections with either clinical or radiographic malperfusion, which…
ATLANTA, June 10, 2026 /PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that it will participate at the upcoming 2026 Truist Securities MedTech Conference on Tuesday, June 16, 2026, at the Boston Harbor Hotel. The Company's fireside chat is scheduled to begin at 1:00 p.m.
Endospan, a pioneer in endovascular solutions for complex aortic pathologies, today announced that Artivion, Inc. (NYSE: AORT) has closed the transaction to ac
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.